lung cancer
impact of cancer
cancer incidences
cancer diagnostics intellectual property
early cancer diagnosis
diagnostics technology
overall cancer care costs
BSI’s IP-based diagnostics
global diagnostics market
major European diagnostics company
integrated diagnostics companies
BSI novel biomarkers
Multiplex Protein Epitope Profiling Cancer incidence
overall care costs diagnosis
candidate diagnostic
business plan
health care system
business opportunity
business model
colon cancers
CANDLE project objective
complete clinical validation
specific diagnostic tests
cost-effective diagnostic products
better health outcomes
plasma protein epitome biomarker panels
better terms
promising results
earlier detection
major concern of European governments
validated results
BSI’s competitiveness
license revenues
earlier qualification stage
citizens’ lives
patient
survival
sustainability
return
competitive advantage
breast
proof
investments
profitability
higher royalties
concept
needs
BioSystems International Kft
innovation activity
years
Euros